Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways / Yosef Yarden, Moshe Elkabets, editors.
Yarden, Y. (Yosef), editor.; Elkabets, Moshe, editor.
2018
RC271.C5
Available Online

Linked e-resources

Linked Resource
Online Access
Concurrent users
Unlimited
Authorized users
Authorized users
Document Delivery Supplied
Can lend chapters, not whole ebooks

Details

Title
Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways / Yosef Yarden, Moshe Elkabets, editors.
ISBN
9783319679327 (electronic book)
3319679325 (electronic book)
9783319679303
3319679309
DOI
https://doi.org/10.1007/978-3-319-67932-7
Published
Cham, Switzerland : Springer, 2018.
Language
English
Description
1 online resource.
Item Number
10.1007/978-3-319-67932-7 doi
Call Number
RC271.C5
Dewey Decimal Classification
616.99/4061
Summary
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Bibliography, etc. Note
Includes bibliographical references and index.
Access Note
Access limited to authorized users.
Digital File Characteristics
text file PDF
Source of Description
Online resource; title from PDF title page (SpringerLink, viewed April 5, 2018).
Added Author
Yarden, Y. (Yosef), editor.
Elkabets, Moshe, editor.
Series
Resistance to targeted anti-cancer therapeutics ; v. 15.
Available in Other Form
Print version: 3319679309
Linked Resources
Online Access
Record Appears in
Online Resources > Ebooks
All Resources
Resistance of colorectal tumors to anti-EGFR antibodies
Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK
Mechanisms of action and resistance of trastuzumab in breast cancer
Mechanisms of resistance to molecular therapies targeting the HGF/MET axis
RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge
Mechanisms of resistance to PI3K and AKT inhibitors
Sensitivity and resistance to BH3 mimetics in cancer therapy
Resistance mechanisms to cyclin-dependent kinase inhibitors
Resistance to inhibitors of angiogenesis.

Browse Subjects

Show more subjects...

Statistics

from
to
Export